Flex Pharma to Report Third Quarter 2017 Results on November 6, 2017
BOSTON--(BUSINESS WIRE)--Nov. 2, 2017--
to Tweet this News
Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company
that is developing innovative and proprietary treatments for cramps and
spasticity associated with severe neurological diseases such as multiple
sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral
sclerosis (ALS) under FDA Fast Track designation, announced today that
it will report its financial results for the third quarter ended
September 30, 2017 on Monday, November 6, 2017 before the U.S. financial
markets open. The Company will host a conference call and webcast at
8:45 a.m. ET to discuss third quarter 2017 financial results and provide
a business update. Individuals interested in participating in the call
should dial (855) 780-7202 (U.S. and Canada) or (631) 485-4874
A live webcast may be accessed in the Investors section of the Company's
website at www.flex-pharma.com.
Please log on to the Flex Pharma website approximately 15 minutes prior
to the scheduled webcast to ensure adequate time for any software
downloads that may be required. A replay of the webcast will be
available on Flex Pharma's website for three months.
About Flex Pharma
Flex Pharma, Inc. is a clinical-stage biotechnology company that is
developing innovative and proprietary treatments for cramps and
spasticity associated with the severe neurological diseases of ALS, MS
and peripheral neuropathies such as Charcot-Marie-Tooth (CMT). The
Company’s lead candidate, FLX-787, is being developed under Fast Track
designation for the treatment of severe muscle cramps associated with
ALS. Flex Pharma was founded by National Academy of Science members Rod
MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized
leaders in the fields of ion channels and neurobiology, along with
Christoph Westphal, M.D., Ph.D.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171102005784/en/
Source: Flex Pharma, Inc.
Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
Relations & Corporate Communications